About Novilla Pharmaceuticals

Novilla is developing a patented drug delivery system that provides an alternative to opioids for pain management. This technology aims to mitigate the public health crisis posed by the opioid epidemic by offering a safer therapeutic option.

```xml <problem> The opioid epidemic poses a significant public health crisis, creating a need for safer and non-addictive pain management alternatives. Traditional drug delivery methods often expose the entire body to therapeutics, leading to unwanted side effects and potential addiction risks. </problem> <solution> Novilla Pharmaceuticals is developing a patented drug delivery platform designed to bypass the bloodstream, delivering therapeutics directly to the site of action. This targeted approach aims to maximize efficacy while minimizing systemic exposure, thereby reducing side effects and the risk of addiction. The platform seeks to provide an alternative to opioids for pain management by enhancing the penetration of existing therapies into the dermal layer. By avoiding systemic circulation, Novilla's technology intends to create fundamentally better therapeutics with full efficacy and a reduced risk profile. </solution> <features> - Patented drug delivery system for targeted therapeutic administration. - Bypasses the bloodstream to minimize systemic exposure. - Enhances dermal penetration of existing therapies. - Designed to reduce side effects and addiction risks associated with traditional pain management. </features> <target_audience> The primary target audience includes patients seeking non-opioid pain management options and pharmaceutical companies looking to improve the safety and efficacy of their existing pain therapeutics. </target_audience> ```

What does Novilla Pharmaceuticals do?

Where is Novilla Pharmaceuticals located?

Novilla Pharmaceuticals is based in Washington, United States.

When was Novilla Pharmaceuticals founded?

Novilla Pharmaceuticals was founded in 2019.

How much funding has Novilla Pharmaceuticals raised?

Novilla Pharmaceuticals has raised 9000000.

Location

Washington, United States

Founded

2019

Funding

9000000

Employees

12 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Novilla Pharmaceuticals

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

novilla.com 300+

Crunchbase

Founded 2019 – Washington, United States

Funding

Estimated Funding

$5M+

Team (10+)

No team information available.

Company Description

Problem

The opioid epidemic poses a significant public health crisis, creating a need for safer and non-addictive pain management alternatives. Traditional drug delivery methods often expose the entire body to therapeutics, leading to unwanted side effects and potential addiction risks.

Solution

Novilla Pharmaceuticals is developing a patented drug delivery platform designed to bypass the bloodstream, delivering therapeutics directly to the site of action. This targeted approach aims to maximize efficacy while minimizing systemic exposure, thereby reducing side effects and the risk of addiction. The platform seeks to provide an alternative to opioids for pain management by enhancing the penetration of existing therapies into the dermal layer. By avoiding systemic circulation, Novilla's technology intends to create fundamentally better therapeutics with full efficacy and a reduced risk profile.

Features

Patented drug delivery system for targeted therapeutic administration.

Bypasses the bloodstream to minimize systemic exposure.

Enhances dermal penetration of existing therapies.

Designed to reduce side effects and addiction risks associated with traditional pain management.

Target Audience

The primary target audience includes patients seeking non-opioid pain management options and pharmaceutical companies looking to improve the safety and efficacy of their existing pain therapeutics.